PSCH:NSD-Invesco S&P SmallCap Health Care ETF (USD)

ETF | Health |

Last Closing

USD 44.44

Change

0.00 (0.00)%

Market Cap

USD 0.18B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices, LLC compiles, maintains and calculates the index, which is designed to measure the performance of securities of small-capitalization U.S. companies in the health care sector, as defined by the Global Industry Classification Standard.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

N/A

USD 6.55B
PPH VanEck Pharmaceutical ETF

N/A

USD 0.67B
BBH VanEck Biotech ETF

N/A

USD 0.43B
PTH Invesco DWA Healthcare Momentu..

N/A

USD 0.14B
GNOM Global X Genomics & Biotechnol..

N/A

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

N/A

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

N/A

USD 0.01B

ETFs Containing PSCH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.83% 75% C 56% F
Dividend Return 0.24% 40% F 3% F
Total Return 4.07% 75% C 52% F
Trailing 12 Months  
Capital Gain 18.63% 75% C 65% D
Dividend Return 0.28% 33% F 2% F
Total Return 18.92% 75% C 63% D
Trailing 5 Years  
Capital Gain 9.10% 38% F 56% F
Dividend Return 0.26% 29% F 1% F
Total Return 9.36% 38% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 1.86% 50% F 44% F
Dividend Return 1.89% 50% F 40% F
Total Return 0.02% 38% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 31.22% 50% F 60% D-
Risk Adjusted Return 6.05% 38% F 39% F
Market Capitalization 0.18B 63% D 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.